FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894046119> ?p ?o ?g. }

• W2894046119 endingPage "959" @default.
• W2894046119 startingPage "952" @default.
• W2894046119 abstract "Several authors have hypothesized that adverse drug events (ADEs) upon switching from reference biologics to biosimilar products are related to the nocebo effect. However, a thorough and current review of the existing literature has not been conducted.To evaluate if patient and/or physician knowledge of a switch from a reference biologic product to a biosimilar product was associated with an increase in ADEs likely to be susceptible to the nocebo effect.Studies reporting efficacy and safety outcomes of a switch from a reference product to a biosimilar product were reviewed. Biologics with FDA-approved biosimilars in the United States were considered for review, including adalimumab, bevacizumab, etanercept, and infliximab. Studies were identified by searching controlled vocabulary (e.g., MeSH terms) and keywords within MEDLINE (via PubMed) and Embase. Descriptive statistics were used to quantify subjective and objective complications in double-blinded and single-blinded or open-label studies.Thirty-one trials including 3,271 patients were reviewed in the full analysis. Median discontinuation rates for any reason were 14.3% (range = 0.0-33.3) in open-label studies compared with 6.95% (range = 5.2-11.0) in double-blinded studies. Discontinuation rates for ADEs were 5.6% (range = 0.0-24.2) in open-label studies versus 3.1% (range = 2.0-5.2) in double-blinded studies, suggesting the nocebo effect does affect biosimilar adoption. Subgroup analyses of antidrug antibody (ADA) development and infusion reactions were similar between infliximab open-label and double-blinded studies. Discontinuation rates for any reason, for ADEs, and for lack of efficacy were generally higher in infliximab open-label trials compared with double-blinded trials. Etanercept biosimilar discontinuation rates for any reason were similar between study designs; however, incidences of injection site reactions and discontinuation rates for ADEs were higher in double-blinded compared with open-label study designs.Current evidence is insufficient to confirm a biosimilar nocebo effect, although higher discontinuation rates in infliximab biosimilar open-label studies support this theory. Further studies are needed to evaluate the existence of a biosimilar nocebo effect.No outside funding supported this study. The authors have no conflicts of interest to disclose." @default.
• W2894046119 created "2018-10-05" @default.
• W2894046119 creator A5045807193 @default.
• W2894046119 creator A5059170804 @default.
• W2894046119 creator A5061592940 @default.
• W2894046119 creator A5091298649 @default.
• W2894046119 date "2018-10-01" @default.
• W2894046119 modified "2023-10-14" @default.
• W2894046119 title "The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies" @default.
• W2894046119 cites W1827882046 @default.
• W2894046119 cites W1997613912 @default.
• W2894046119 cites W2022888597 @default.
• W2894046119 cites W2063836318 @default.
• W2894046119 cites W2089015826 @default.
• W2894046119 cites W2106152050 @default.
• W2894046119 cites W2130173462 @default.
• W2894046119 cites W2292127106 @default.
• W2894046119 cites W2317502128 @default.
• W2894046119 cites W2342216265 @default.
• W2894046119 cites W2342464058 @default.
• W2894046119 cites W2345220764 @default.
• W2894046119 cites W2479896075 @default.
• W2894046119 cites W2482832580 @default.
• W2894046119 cites W2508045778 @default.
• W2894046119 cites W2517898512 @default.
• W2894046119 cites W2521883132 @default.
• W2894046119 cites W2543281533 @default.
• W2894046119 cites W2545293585 @default.
• W2894046119 cites W2578994901 @default.
• W2894046119 cites W2581549770 @default.
• W2894046119 cites W2586796756 @default.
• W2894046119 cites W2589454171 @default.
• W2894046119 cites W2593580677 @default.
• W2894046119 cites W2595989365 @default.
• W2894046119 cites W2610308940 @default.
• W2894046119 cites W2610498431 @default.
• W2894046119 cites W2611064734 @default.
• W2894046119 cites W2613299853 @default.
• W2894046119 cites W2614161127 @default.
• W2894046119 cites W2620165699 @default.
• W2894046119 cites W2623636343 @default.
• W2894046119 cites W2624289061 @default.
• W2894046119 cites W2676374412 @default.
• W2894046119 cites W2732307662 @default.
• W2894046119 cites W2733382837 @default.
• W2894046119 cites W2733544055 @default.
• W2894046119 cites W2744523261 @default.
• W2894046119 cites W2748407913 @default.
• W2894046119 cites W2751387666 @default.
• W2894046119 cites W2755232362 @default.
• W2894046119 cites W2759349664 @default.
• W2894046119 cites W2762604306 @default.
• W2894046119 cites W2763735374 @default.
• W2894046119 cites W2764082441 @default.
• W2894046119 cites W2766388803 @default.
• W2894046119 cites W2766809453 @default.
• W2894046119 cites W2767179430 @default.
• W2894046119 cites W2767727558 @default.
• W2894046119 cites W2769933631 @default.
• W2894046119 cites W2774116866 @default.
• W2894046119 cites W2784409714 @default.
• W2894046119 cites W2786419811 @default.
• W2894046119 cites W2794339583 @default.
• W2894046119 cites W849320553 @default.
• W2894046119 doi "https://doi.org/10.18553/jmcp.2018.24.10.952" @default.
• W2894046119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30247100" @default.
• W2894046119 hasPublicationYear "2018" @default.
• W2894046119 type Work @default.
• W2894046119 sameAs 2894046119 @default.
• W2894046119 citedByCount "44" @default.
• W2894046119 countsByYear W28940461192019 @default.
• W2894046119 countsByYear W28940461192020 @default.
• W2894046119 countsByYear W28940461192021 @default.
• W2894046119 countsByYear W28940461192022 @default.
• W2894046119 countsByYear W28940461192023 @default.
• W2894046119 crossrefType "journal-article" @default.
• W2894046119 hasAuthorship W2894046119A5045807193 @default.
• W2894046119 hasAuthorship W2894046119A5059170804 @default.
• W2894046119 hasAuthorship W2894046119A5061592940 @default.
• W2894046119 hasAuthorship W2894046119A5091298649 @default.
• W2894046119 hasBestOaLocation W28940461191 @default.
• W2894046119 hasConcept C126322002 @default.
• W2894046119 hasConcept C142724271 @default.
• W2894046119 hasConcept C17744445 @default.
• W2894046119 hasConcept C177713679 @default.
• W2894046119 hasConcept C17991360 @default.
• W2894046119 hasConcept C197934379 @default.
• W2894046119 hasConcept C199539241 @default.
• W2894046119 hasConcept C204787440 @default.
• W2894046119 hasConcept C27081682 @default.
• W2894046119 hasConcept C2777138892 @default.
• W2894046119 hasConcept C2777575956 @default.
• W2894046119 hasConcept C2778360308 @default.
• W2894046119 hasConcept C2778715236 @default.
• W2894046119 hasConcept C2779473830 @default.
• W2894046119 hasConcept C2780132546 @default.
• W2894046119 hasConcept C2909182145 @default.
• W2894046119 hasConcept C59491497 @default.

• next